4893 Noile-Immune Biotech Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4893

TSE Growth

Noile-Immune Biotech Inc.

161

JPY

(0.00%)

Dec 5, 3:30 pm JST

1.04

USD

Dec 5, 1:30 am EST

Result

PTS

outside of trading hours

160.9

Dec 5, 3:23 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2021 ＊	100	-767	-792	-795	-20.8	0	ー	J-GAAP
Dec, 2022 ＊	625	-106	-384	-386	-9.9	0	ー	J-GAAP
Dec, 2023	316	-775	-1,127	-1,130	-27.3	0	Feb 13, 2024	J-GAAP
Dec, 2024	7	-1,069	-962	-964	-22.3	0	Feb 14, 2025	J-GAAP
Dec, 2025 Guidance	5	-812	-806	-809	-18.7	0	Nov 13, 2025	J-GAAP
YoY	-28.6%	+24.0%	+16.2%	+16.1%	+16.2%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2023	Jun 28, 2023	319	-1,535	-1,832	-1,834	0	J-GAAP
	Jan 25, 2024	316	-775	-1,127	-1,130	0	J-GAAP
Results	Feb 13, 2024	316	-775	-1,127	-1,130	0	J-GAAP
Dec, 2024	Feb 13, 2024	Available in future release
	Nov 14, 2024
Results	Feb 14, 2025
Dec, 2025	Feb 14, 2025	ー	ー	ー	ー	0	J-GAAP
- - - -	Nov 13, 2025	5	-812	-806	-809	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2017	27	－	Available in future release
Dec, 2018	1,558	+5,670.4
Dec, 2019	521	-66.6
Dec, 2020	97	-81.4
Dec, 2021	100	+3.1
Dec, 2022	625	+525.0
Dec, 2023	316	-49.4
Dec, 2024	7	-97.8
Dec, 2025 Guidance	5	-28.6	-812	+24.0	-806	+16.2	-18.7	+16.1

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2023	316	-775	-245	-22.66	-21.69	0.06	-27.3
Dec, 2024	7	-1,069	-15,271	-18.54	-18.23	ー	-22.3
Dec, 2025 Guidance	5	-812	-16,240	-19.67	-19.29	ー	-18.7

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,558	-106	1,192	872	25.7
Fiscal Year	Dec, 2018	Dec, 2022	Dec, 2018	Dec, 2018	Dec, 2018

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2022	612	275	11	10	0.3	0	ー	J-GAAP
Jul - Dec, 2023	305	-294	-295	-297	-7.2	0	Feb 13, 2024	J-GAAP
Jul - Dec, 2024	5	-388	-280	-281	-6.5	0	Feb 14, 2025	J-GAAP
Jul - Dec, 2025 Guidance	1	-400	-396	-398	-9.2	0	Nov 13, 2025	J-GAAP
YoY	-80.0%	-3.1%	-41.4%	-41.6%	-41.6%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2022	-106	ー	-107	ー	487	4,520	97.39	J-GAAP
Dec, 2023	-775	-878	-873	-5	1,913	5,555	96.14	J-GAAP
Dec, 2024	-1,069	-887	-887	0	2	4,670	97.29	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2023	314	-495	-848	-850	-20.8	ー	Nov 13, 2023	J-GAAP
Jan - Sep, 2024	5	-892	-785	-787	-18.2	ー	Nov 14, 2024	J-GAAP
Jan - Sep, 2025	5	-608	-602	-605	-14.0	ー	Nov 13, 2025	J-GAAP
YoY	0.0%	+31.8%	+23.3%	+23.1%	+23.2%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	2	-280	-279	-280	-6.8	-14,000.0	Feb 13, 2024	J-GAAP
Jan - Mar, 2024	2	-339	-339	-340	-7.9	-16,950.0	May 14, 2024	J-GAAP
Apr - Jun, 2024	0	-342	-343	-343	-7.9	-Inf	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	3	-211	-103	-104	-2.4	-7,033.3	Nov 14, 2024	J-GAAP
Oct - Dec, 2024	2	-177	-177	-177	-4.1	-8,850.0	Feb 14, 2025	J-GAAP
Jan - Mar, 2025	2	-241	-239	-240	-5.6	-12,050.0	May 12, 2025	J-GAAP
Apr - Jun, 2025	2	-171	-171	-171	-4.0	-8,550.0	Aug 8, 2025	J-GAAP
Jul - Sep, 2025	1	-196	-192	-194	-4.5	-19,600.0	Nov 13, 2025	J-GAAP
YoY	-66.7%	+7.1%	-86.4%	-86.5%	-86.7%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2022	7	－	Available in future release
Apr - Jun, 2022	6	－
Jul - Sep, 2022	607	－
Oct - Dec, 2022	5	－
Jan - Mar, 2023	8	+14.3
Apr - Jun, 2023	3	-50.0
Jul - Sep, 2023	303	-50.1
Oct - Dec, 2023	2	-60.0
Jan - Mar, 2024	2	-75.0
Apr - Jun, 2024	0	-100.0
Jul - Sep, 2024	3	-99.0
Oct - Dec, 2024	2	0.0
Jan - Mar, 2025	2	0.0
Apr - Jun, 2025	2	－
Jul - Sep, 2025	1	-66.7	-196	+7.1	-192	-86.4	-4.5	-87.5

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	607	432	429	428	11.2
Fiscal Year	Sep, 2022	Sep, 2022	Sep, 2022	Sep, 2022	Sep, 2022

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2022	108.48	92.5	4,641	4,293	-1,259	ー	ー	J-GAAP
Dec, 2023	131.26	98.3	5,778	5,680	-2,389	ー	Feb 13, 2024	J-GAAP
Dec, 2024	108.97	98.3	4,800	4,718	-3,353	ー	Feb 14, 2025	J-GAAP
Jan - Sep, 2025	ー	98.1	4,194	4,113	-3,958	ー	Nov 13, 2025	J-GAAP

Noile-Immune Biotech Inc.(4893) Financial Results